United Therapeutics Corporation (UTHR) : Scopia Capital Management Lp reduced its stake in United Therapeutics Corporation by 4.85% during the most recent quarter end. The investment management company now holds a total of 4,092,701 shares of United Therapeutics Corporation which is valued at $549,854,379 after selling 208,651 shares in United Therapeutics Corporation , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.United Therapeutics Corporation makes up approximately 11.21% of Scopia Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Two Sigma Advisers Lp reduced its stake in UTHR by selling 54,100 shares or 17.48% in the most recent quarter. The Hedge Fund company now holds 255,373 shares of UTHR which is valued at $34,309,363. United Therapeutics Corporation makes up approx 0.15% of Two Sigma Advisers Lp’s portfolio. Bks Advisors sold out all of its stake in UTHR during the most recent quarter. The investment firm sold 6,400 shares of UTHR which is valued $831,872.Ncm Capital Advisers reduced its stake in UTHR by selling 132 shares or 7.21% in the most recent quarter. The Hedge Fund company now holds 1,700 shares of UTHR which is valued at $203,235. United Therapeutics Corporation makes up approx 0.62% of Ncm Capital Advisers’s portfolio.State Treasurer State Of Michigan reduced its stake in UTHR by selling 400 shares or 2.23% in the most recent quarter. The Hedge Fund company now holds 17,500 shares of UTHR which is valued at $2,081,450. United Therapeutics Corporation makes up approx 0.02% of State Treasurer State Of Michigan’s portfolio.Mitsubishi Ufj Kokusai Asset Management Ltd. boosted its stake in UTHR in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 6,373 shares of United Therapeutics Corporation which is valued at $765,206. United Therapeutics Corporation makes up approx 0.02% of Mitsubishi Ufj Kokusai Asset Management Ltd.’s portfolio.
United Therapeutics Corporation closed down -2.57 points or -1.92% at $130.94 with 4,55,716 shares getting traded on Monday. Post opening the session at $133.5, the shares hit an intraday low of $130.49 and an intraday high of $133.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, United Therapeutics Corporation reported $4.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.43 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $3.93. The company had revenue of $408.20 million for the quarter, compared to analysts expectations of $402.93 million. The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.55 EPS.
Many Wall Street Analysts have commented on United Therapeutics Corporation. United Therapeutics Corporation was Upgraded by Ladenburg Thalmann to ” Buy” on Oct 28, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.